SCHEMBL16210465

SCHEMBL16210465

COC1(C(=O)NC2(C)CCC2)CCN(C2CCCN(C(=O)OC(C)(C)C)CC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.55
HPGD P15428 1/20 0.41
HRH3 Q9Y5N1 3/20 0.41
EPHX1 P07099 1/20 0.40
HCAR1 Q9BXC0 1/20 0.38
CTSD P07339 1/20 0.37
CTSE P14091 1/20 0.37
BACE1 P56817 1/20 0.37
EPHX2 P34913 1/20 0.36
ALDH1A1 P00352 2/20 0.36
OPRM1 P35372 1/20 0.35
OPRD1 P41143 1/20 0.35
OGFRL1 Q5TC84 1/20 0.35
ABL1 P00519 1/20 0.35
RIN1 Q13671 1/20 0.35
ACACB O00763 1/20 0.35
ACACA Q13085 1/20 0.35
RECQL P46063 1/20 0.35
PTPN2 P17706 1/20 0.35
PTPN1 P18031 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14964734 0.87 CHRM1 (0.53) CHRM1HRH3ALDH1A1KDM4EPKM
SCHEMBL14978786 0.86 CHRM1 (0.70) CHRM1ALDH1A1KDM4EPKMMEN1
SCHEMBL16210842 0.85 HPGD (0.46) CHRM1HPGDHRH3EPHX1HCAR1
SCHEMBL16210661 0.83 HPGD (0.47) CHRM1HPGDHRH3EPHX1HCAR1
SCHEMBL14978785 0.81 CHRM1 (0.56) CHRM1ALDH1A1KDM4EPKMMEN1
SCHEMBL14968758 0.79 CHRM1 (0.42) CHRM1HRH3
SCHEMBL24183612 0.75 HPGD (0.64) HPGDEPHX1HCAR1ALDH1A1OPRM1
SCHEMBL2157153 0.75 HPGD (0.49) CHRM1HPGDHRH3EPHX1EPHX2
SCHEMBL4827509 0.75 HPGD (0.49) CHRM1HPGDHRH3EPHX1CTSD
SCHEMBL16217946 0.75 CHRM1 (0.73) CHRM1ALDH1A1KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11793817-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2023-10-24 US disclosed
US-20210353637-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2021-11-18 US disclosed
US-10973832-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2021-04-13 US disclosed
US-20200253982-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2020-08-13 US disclosed
US-10413553-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2019-09-17 US disclosed
US-20180153900-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2018-06-07 US disclosed
US-9907805-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2018-03-06 US disclosed
US-20170157139-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2017-06-08 US disclosed
US-9573929-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2017-02-21 US disclosed
EP-2780015-B1 MUSCARINIC M1 RECEPTOR AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2017-01-04 EP disclosed
US-20160068508-A1 Muscarinic M1 Receptor Agonists NXERA PHARMA UK LIMITED (GB) 2016-03-10 US disclosed
US-9187451-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2015-11-17 US disclosed
US-20140329803-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2014-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329803-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885HRH3 85/4885
US-20180153900-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885HRH3 85/4885
US-20160068508-A1 Muscarinic M1 Receptor Agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885HRH3 85/4885
US-20200253982-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885HRH3 85/4885
US-20210353637-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885HRH3 85/4885
US-20170157139-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885HRH3 85/4885
US-10973832-B2 Muscarinic M1 receptor agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885HRH3 85/4885
US-10413553-B2 Muscarinic M1 receptor agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885HRH3 85/4885
US-11793817-B2 Muscarinic M1 receptor agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885HPGD 2584/4885HRH3 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.